Top stocks in focus: HDFC Standard Life, Jet Airways, TVS Motor, NHPC

Check out the companies which will be in focus during trade today based on recent and latest news developments.

Mar 12, 2019 02:03 IST India Infoline News Service

HDFC Standard Life Insurance stock in focus today as Standard Life (Mauritius Holdings) said it will sell via offer for sale mechanism up to 7cr shares, or 3.47% of the equity shares with an option to sell an additional 2.95cr shares aggregating to a sale stake of 4.93% stake in the Insurance company.

Jet Airways denied that it received Rs2,050cr as a loan from PNB. The company has clarified that it has existing credit facilities of $300 mn from the bank and no fresh credit facilities have been provided. As per media reports stated that it is not flying any Boeing 737 Max Plane and the company says it in contact with manufacturers and regulators to ensure all directives are implemented.

TVS Motor
declares second interim dividend of Rs1.40 per share.

NHPC planned a capex of Rs3,800cr for financial year 2020 and to bid for JAL Power in NCLT, as per media reports.

Welspun Corp received additional pipe order of 212 KMT. The company stated that its order book stood at 1667 KMTs valued at Rs14,500c.

TRF said it was looking to issue Rs250cr worth of preference shares to Tata Steel in order to restructure the balance sheet and repay debts.

The Reserve Bank of India has imposed a penalty of Rs1cr on Corporation Bank due to deficiency in regulatory compliance.

KEI Industries said the second phase of capex for medium voltage cables in Rajasthan was operational.

Selan Exploration received letter of approval from Ministry of Petroleum and Natural Gas for grant of extension of 10 years with effect from March 2020 for Lohar Field.

Kalpataru Power Transmission increased its stake in Shree Shubham Logistics from 71.52% to 80.06%.

PSP Projects received work orders worth Rs601cr from various clients. The total work orders for financial year 2019 (till date) stand at Rs1,442.47cr.

Laurus Labs received a final approval from USFDA for Hydroxychloroquine Tablets 200 mg and a tentative approval for an ANDA for ADL Tablets 600 mg/50 mg/300 mg.

Related Story